Administration of nicotinamide mononucleotide in the treatment of disease
Disclosed are methods and compositions related to methods of treating, ameliorating, mitigating, slowing, arresting, preventing or reversing various diseases and conditions, including age-related obesity, age-related increases in blood lipid levels, age-related decreases in insulin sensitivity, age-related decreases in memory function, and age-related changes in eye function such as macular degeneration. The methods comprise administering nicotinamide mononucleotide (NMN) to a subject. In some embodiments, the administration can be oral administration. Also disclosed are pharmaceutical compositions comprising NMN.
1. A method of increasing bone density in a subject need thereof, comprising: administering to a subject in need of treatment a pharmaceutically effective amount of nicotinamide mononucleotide (NMN).
2. A method in accordance with claim 1 , wherein the subject is a subject in need of treatment for age-associated bone density decrease.
3. A method in accordance with claim 1 , wherein the subject is a subject in need of treatment for osteoporosis.
4. A method in accordance with claim 1 , wherein the NMN is administered orally in a pharmaceutically acceptable formulation selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, a powder, a granule, an effervescent tablet, a hard gelatin capsule, a soft gelatin capsule, a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, and a lyophilized formulation.
5. A method in accordance with claim 1 , wherein the NMN is administered parenterally in a pharmaceutically acceptable formulation selected from the group consisting of a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, a lyophilized formulation.
6. A method in accordance with claim 1 , wherein the NMN is administered intravenously.
7. A method in accordance with claim 1 , wherein the NMN is administered enterically.
8. A method of treating aberrantly low bone density in a subject in need thereof, comprising: administering to a subject in need of treatment a pharmaceutically effective amount of nicotinamide mononucleotide (NMN).
9. A method in accordance with claim 8 , wherein the aberrantly low bone density is an age-associated aberrantly low bone density.
10. A method in accordance with claim 8 , wherein the aberrantly low bone density is osteoporosis.
11. A method in accordance with claim 8 , wherein the NMN is administered orally in a pharmaceutically acceptable formulation selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, a powder, a granule, an effervescent tablet, a hard gelatin capsule, a soft gelatin capsule, a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, and a lyophilized formulation.
12. A method in accordance with claim 8 , wherein the NMN is administered parenterally in a pharmaceutically acceptable formulation selected from the group consisting of a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, a lyophilized formulation.
13. A method in accordance with claim 8 , wherein the NMN is administered intravenously.
14. A method in accordance with claim 8 , wherein the NMN is administered enterically.
15. A method of treating an age-associated bone disorder in a subject in need thereof, comprising: administering to a subject a pharmaceutically effective amount of nicotinamide mononucleotide (NMN).
16. A method in accordance with claim 15 , wherein the age-associated bone disorder is age-associated osteoporosis.
17. A method in accordance with claim 15 , wherein the NMN is administered orally in a pharmaceutically acceptable formulation selected from the group consisting of a pill, a tablet, a caplet, a capsule, a chewable tablet, a quick dissolve tablet, a powder, a granule, an effervescent tablet, a hard gelatin capsule, a soft gelatin capsule, a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, and a lyophilized formulation.
18. A method in accordance with claim 15 , wherein the NMN is administered parenterally in a pharmaceutically acceptable formulation selected from the group consisting of a non-aqueous liquid, an aqueous liquid, a suspension, a solution, an emulsion, a syrup, a sterilized aqueous suspension, a sterilized aqueous solution, a non-aqueous suspension, a non-aqueous solution, a lyophilized formulation.
19. A method in accordance with claim 15 , wherein the NMN is administered intravenously.
20. A method in accordance with claim 15 , wherein the NMN is administered enterically.